218 related articles for article (PubMed ID: 36326913)
1. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
[TBL] [Abstract][Full Text] [Related]
2. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
[TBL] [Abstract][Full Text] [Related]
4. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors.
Guven DC; Ozbek DA; Sahin TK; Kavgaci G; Aksun MS; Erul E; Yildirim HC; Chalabiyev E; Cebroyilov C; Yildirim T; Dizdar O; Aksoy S; Yalcin S; Kilickap S; Erman M; Arici M
Anticancer Drugs; 2023 Jul; 34(6):783-790. PubMed ID: 36729111
[TBL] [Abstract][Full Text] [Related]
5. Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.
Zhou P; Liu B; Shen N; Fan X; Lu S; Kong Z; Gao Y; Lv Z; Wang R
Ren Fail; 2024 Dec; 46(1):2326186. PubMed ID: 38466161
[TBL] [Abstract][Full Text] [Related]
6. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence.
Xie W; Xiao S; Li X; Huang J; Li G; Zhang Z
Eur J Intern Med; 2023 Sep; 115():88-95. PubMed ID: 37263805
[TBL] [Abstract][Full Text] [Related]
7. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
[TBL] [Abstract][Full Text] [Related]
8. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
10. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
[No Abstract] [Full Text] [Related]
11. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.
Baker ML; Yamamoto Y; Perazella MA; Dizman N; Shirali AC; Hafez N; Weinstein J; Simonov M; Testani JM; Kluger HM; Cantley LG; Parikh CR; Wilson FP; Moledina DG
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35354588
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study.
Koks MS; Ocak G; Suelmann BBM; Hulsbergen-Veelken CAR; Haitjema S; Vianen ME; Verhaar MC; Kaasjager KAH; Khairoun M
PLoS One; 2021; 16(6):e0252978. PubMed ID: 34101756
[TBL] [Abstract][Full Text] [Related]
15. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
16. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
[TBL] [Abstract][Full Text] [Related]
17. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury.
Dreischulte T; Morales DR; Bell S; Guthrie B
Kidney Int; 2015 Aug; 88(2):396-403. PubMed ID: 25874600
[TBL] [Abstract][Full Text] [Related]
18. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
[TBL] [Abstract][Full Text] [Related]
19. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
[TBL] [Abstract][Full Text] [Related]
20. Acute kidney injury in patients receiving immune checkpoint inhibitors: a retrospective real-world study.
Lumlertgul N; Vassallo P; Tydeman F; Lewis N; Hobill A; Weerapolchai K; Nordin NZ; Seylanova N; Martin L; Cennamo A; Wang Y; Rigg A; Shaunak N; Ostermann M
Eur J Cancer; 2023 Sep; 191():112967. PubMed ID: 37499561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]